抄録
Aim: To retrospectively evaluate the feasibility and safety of repeated transarterial chemoembolization (TACE) three or more times using miriplatin-lipiodol (MLPD) suspension (repeated M-LPD TACE) for hepatocellular carcinoma (HCC). Patients and Methods: Sixteen patients who underwent repeated M-LPD TACE were examined. Total dose of miriplatin, lipiodol and porous gelatin sponge particles and adverse events of the first and last M-LPD TACE were evaluated. Results: The mean±standard deviation (SD) of the total number of M-LPD TACE per patient was 3.7±1.1. The mean±SD dose of total miriplatin, lipiodol and porous gelatin sponge particles per patient was 303±103 mg, 21±7.3 ml and 84±57 mg, respectively. There were no significant differences in any adverse events between the first and last M-LPD TACE. Conclusion: Repeated M-LPD TACE for HCC is feasible and safe in selected patients.
本文言語 | English |
---|---|
ページ(範囲) | 3183-3187 |
ページ数 | 5 |
ジャーナル | Anticancer research |
巻 | 37 |
号 | 6 |
DOI | |
出版ステータス | Published - 2017 6月 |
外部発表 | はい |
ASJC Scopus subject areas
- 腫瘍学
- 癌研究